1-97098598-C-T
Variant summary
Our verdict is Uncertain significance. The variant received 1 ACMG points: 1P and 0B. PP3
The NM_000110.4(DPYD):c.2657G>A(p.Arg886His) variant causes a missense change. The variant allele was found at a frequency of 0.000018 in 1,612,928 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000110.4 missense
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 1 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 151970Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.0000439 AC: 11AN: 250320 AF XY: 0.0000444 show subpopulations
GnomAD4 exome AF: 0.0000164 AC: 24AN: 1460840Hom.: 0 Cov.: 31 AF XY: 0.0000165 AC XY: 12AN XY: 726720 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152088Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74342 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
Dihydropyrimidine dehydrogenase deficiency Pathogenic:1Uncertain:2
- -
This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. -
- -
not specified Uncertain:1
Variant summary: DPYD c.2657G>A (p.Arg886His) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4.4e-05 in 250320 control chromosomes. This frequency is not significantly higher than expected for a pathogenic variant in DPYD causing Dihydropyrimidine Dehydrogenase Deficiency (4.4e-05 vs 0.0025), allowing no conclusion about variant significance. c.2657G>A has been reported in the literature in at least one individual with Dihydropyrimidine Dehydrogenase Deficiency, who carried the variant of interest as well as C29R, both in the homozygous state (Vreken_1997, Van Kuilenburg_1999). The variant has also been cited in the literature in panels testing cancer patients for chemotherapy toxicity. These reports do not provide unequivocal conclusions about association of the variant with Dihydropyrimidine Dehydrogenase Deficiency. The variant was reported in an E. Coli based expression system to have 25% residual acitvity, and in a mammalian cell system to have activity similar to wild-type (Vreken_1997, Offer_2014). One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. One laboratory classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at